The nation of Zimbabwe has declined a significant American healthcare agreement worth 367 million US dollars (£272m) spanning five years because of Washington's insistence on confidential data.
This rejection became public following a official document dated December was leaked, revealing that Head of State Emmerson Mnangagwa felt the deal was "unbalanced".
A government representative later stated that the United States was requesting health data for scientific study and commercial gain but was not willing to share the benefits from any future treatments.
"We must now begin the difficult and regrettable process of ending our health aid in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy said the US had donated over $1.9bn for health programmes to Zimbabwe during the past twenty years.
A doctors' association in Zimbabwe has appealed for continued negotiations to secure a deal suitable to both sides so the country's vital HIV programme can continue.
Wider Context
This development follows a similar situation in Kenya, where a high court suspended a related deal with the US after legal challenges were filed about the security of Kenyans' health data.
After resuming the presidency recently, US President Donald Trump has reduced overseas assistance and closed the key foreign aid agency.
USAID had managed assistance for the American government, but Trump stated its spending was "inefficient" and his government was seeking direct bilateral agreements to boost transparency and responsibility.
Based on reports, Sixteen African countries have to date signed these new agreements, constituting over $18.3bn in new funding.
Specifics of the Rejected Deal
This assistance for Zimbabwe would have gone towards "combating HIV/Aids, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"We are confident this collaboration might have yielded extraordinary advantages for Zimbabwean communities, especially the 1.2 million men, women and children presently receiving antiretroviral therapy through US-supported programmes," Tremont commented.
However, government spokesperson Nick Mangwana argued the proposed deal was "asymmetrical".
"Our nation was requested to share its genetic material and health information over an extended period, without any corresponding assurance of access to any medical innovations – like new medicines or tests – that could result from that shared data," he stated.
"Put simply, our nation would provide the raw materials for medical research without any certainty that the end products would be available to our citizens should a new disease outbreak arise."
Sovereignty and Global Health
Mangwana further pointed out that the American exit from the World Health Organization (WHO) and its push of bilateral health agreements were disrupting structures already set up through the international health agency.
Mangwana cited its Pathogen Access and Benefit Sharing scheme designed to deal with potential global health emergencies.
"This system is intended to guarantee that when a country contributes its data, the benefits – including vaccines and treatments – are distributed fairly, not monopolised exclusively by those with the resources to create them."
Zimbabwe's reservations regarding the US deal "are not meant as hostility towards the US," Mangwana stressed.
"We encourage ongoing dialogue with our US partners on how future collaboration might be structured in a manner that honours the sovereignty and interests of both nations."
Health Experts Reaction
A leading public health body said it understood the official position, but recommended that talks should continue given that much of the country's Aids initiatives depended on international support.
"Where specific concerns arise, including those relating to data governance or implementation frameworks, these can often be resolved via technical clarification and mutually agreed protections," the group said.
The situation emphasises the continuing debate between receiving vital international aid and protecting national sovereignty in an increasingly data-driven world.